Business Overview
2011
17
$7.6M
Series A
3
1
Pepticom is a unique Artificial Intelligence (AI) platform company with disruptive technology for peptide discovery. The platform is based on research carried out in the Hebrew University and extensively developed further by the company. Pepticom’s disruptive technology allows for the discovery of quantity and quality innovative peptides and other molecules at a fraction of the time and cost of the traditional laboratory discovery methods. The peptide discovered can be used as drugs, in agriculture and animal well-being.Pepticom is engaged in various discovery projects such as ADAMA in the field of agriculture and with other big companies in the Pharmaceutical filed.
Founders (3)
| Name | Title | Contact | |
|---|---|---|---|
 | ㅤImmanuel Lerner | CEO | |
 | ㅤAmit Michaeli | CTO | 1 |
| ㅤAnwar Rayan |
Board and Advisors (7)
| Name | Title | Contact | |
|---|---|---|---|
 | ㅤDavid Siegel | Board Advisor | |
 | ㅤEyal Agmoni | Board Director | |
 | ㅤGalia Kut | Board Director | |
 | ㅤJonathan Cohen | Board Advisor | |
 | ㅤNeely Ivgy-May | Board Advisor |
Funding Rounds (3)
| Round | Date Announced | Investors | |
|---|---|---|---|
 | ㅤPepticom raises $2.6 million funding round | March 10, 2021 | 1 |
 | ㅤPepticom raises $5 million series A | September 30, 2019 | 1 |
| ㅤPepticom raises series Seed | July 31, 2013 |
M&A Events (0)
Investors (1)
| Investor Name | Investor Type | AUM ($) | |
|---|---|---|---|
 | ㅤChartered Group | Private Equity, Venture Capital | 0 |
Patents (4)
| Patent Title | Status |
|---|---|
| Positive allosteric modulators of gaba a receptor | Application |
| Peptide agonists and antagonists of tlr4 activation | Application |
| Positive allosteric modulators of gabaa receptor | Application |
| Artificial peptides and use thereof for glycogen storage disorders | Application |
Research Publications (3)
| Publication Title | Date Published |
|---|---|
| Computationally Designed Bispecific MD2/CD14 Binding Peptides Show TLR4 Agonist Activity | December 1, 2018 |
| From finance to molecular modeling algorithms: The risk and return heuristic | December 1, 2017 |
| Structural basis of glycogen branching enzyme deficiency and pharmacologic rescue by rational peptide design | July 21, 2015 |
Certifications (0)
AI Technology Stack
3
Pepticom’s unique artificial intelligence (AI) technology streamlines and significantly accelerates the ability to discover advanced peptide-based drug candidates. Pepticom’s AI technology enables the discovery of the most advanced peptide-based drug candidates by searching an enormous set of possible solutions, vastly reducing the risk of failure during development. It covers a chemical-space of 1030 possible molecular options – which is much larger than current screening techniques – while simultaneously filtering out the most suitable candidates with properties such as solubility and permeability amongst others. Optimizing drug discovery means shifting the weight of the discovery effort in-silico, to allow an accelerated search of the entire realm of possible solutions. Pepticom is introducing “Swarm Intelligence 2.0”, in which various bots are able to sense, interact and coordinate a collective intelligence with the addition of evolutionary mechanism of bot-selection. Utilizing AI-driven reinforcement learning, search algorithms, smart grids and scoring functions allows Pepticom to discover better binding peptides at each learning iteration. AI learning helps implement the right conclusions towards finding the optimal peptides for target binding.
News
Jobs (0)